



Research, Advances, Challenges and Perspectives in the Development of Vaccines against Dengue, Zika and Chikungunya Viruses

Guest Editors:

Dr. Wildriss Viranaicken

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Dr. Pascale Krejbich

PIMIT, Processus Infectieux en Milieu Insulaire Tropical, Université de La Réunion, INSERM UMR 1187, CNRS 9192, IRD 249, Plateforme CYROI, 97490 Sainte-Clotilde, Ile de La Réunion, France

Deadline for manuscript submissions:
closed (31 August 2021)

Message from the Guest Editors

To establish vaccines, it is necessary to define the host-pathogen interaction mechanisms and especially the molecular determinants of virulence. Among the challenges, it is necessary to consider the existence of the ADE phenomenon, a possible co-circulation of two or more of these viruses in endemic areas and the high prevalence of Guillain-Barré syndromes during some of these viral infections. A candidate vaccine must therefore be able to avoid inducing this type of response in humans and must be able to be used by the most vulnerable populations in endemic areas such as newborns or pregnant women. The purpose of this Special Issue “Research, advances, challenges and perspectives in the development of vaccines against Dengue, Zika and Chikungunya viruses” is to present the latest research results that advance our knowledge on the progress conception of vaccine strategies against these arboviruses. It is open to the submission of manuscripts, reviews, research, short communications, hypothesis, perspectives and point of view, that describe research or idea that can improve our knowledge on this issue for vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com